Wu Ting-Shuan, Hsiao Tzu-Hung, Chen Chung-Hsing, Li Hsin-Ni, Hung Miao-Neng, Jhan Pei-Pei, Tsai Jia-Rung, Teng Chieh-Lin Jerry
Department of Biomedical Sciences, Chung Shan Medical University, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
Department of Medical Research, Chung Shan Medical University Hospital, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
Clin Proteomics. 2025 Jan 21;22(1):3. doi: 10.1186/s12014-025-09527-7.
The standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.
This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.
Proteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.
The results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.
标准的“7 + 3”诱导方案导致30%的初发急性髓系白血病（AML）患者未达到完全缓解（CR）。我们旨在利用Olink平台比较初发AML患者在接受“7 + 3”诱导治疗后达到和未达到CR的骨髓血浆蛋白质组学图谱。
这项前瞻性研究纳入了43例未经治疗的AML患者，根据对“7 + 3”诱导治疗的反应分为CR组（n = 29）和非CR组（n = 14）。我们采用Olink Explore - 384炎症平台进行蛋白质组学分析，以研究CR组和非CR组之间骨髓血浆蛋白水平的差异。
蛋白质组学分析表明，CR组的骨髓血浆中ARTN和CCL23水平显著高于非CR组。免疫组织化学染色证实，CR组中ARTN（25.40%对7.05%，p = 0.013）和CCL23（24.14%对14.29%，p = 0.039）强染色的组织样本比例更高。这些发现得到了批量RNA测序的证实，表明CR组中ARTN（1.93对 - 0.09；p = 0.003）和CCL23（1.50对0.12；p = 0.021）的mRNA表达水平显著升高。人类蛋白质图谱为我们的发现提供了外部支持。
结果表明，ARTN和CCL23可能作为预测未经治疗的AML对“7 + 3”诱导反应性的生物标志物。使用酶联免疫吸附测定法确定ARTN和CCL23在预测AML化疗敏感性中的作用，可能会在未来提高临床适用性。
